v3.25.3
Notes to the consolidated statements of income - Other operating income and expense (Details) - EUR (€)
€ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Other operating income and expense        
Foreign exchange gains € 36,200 € 61,274 € 301,410 € 180,984
Gains on right-of-use assets, from the sale of fixed assets, clinics and investments 1,097 14,131 7,668 20,952
Revaluation of certain investments (178) 18,107 7,328 79,190
Income attributable to consent agreement on foregone profits from sale of certain pharmaceuticals to non-associated companies   62,369   62,369
Income from strategic transactions and programs 2,405 16,079 10,342 103,576
Other 16,553 19,106 70,488 85,423
Other operating income 56,077 191,066 397,236 532,494
Foreign exchange losses 47,958 74,248 338,678 209,471
Losses on right-of-use assets, from the sale of fixed assets, clinics and investments 5,200 5,881 8,162 8,951
Revaluation of certain investments 5,027   70,173  
Expenses from strategic transactions and programs 53,225 3,897 94,084 266,327
Other 13,864 35,483 65,747 66,512
Other operating expense 125,274 119,509 576,844 551,261
Reclassification adjustments of foreign currency translation amounts previously classified within other comprehensive income, included in expenses from strategic transactions and programs (45,083) 14 € (46,088) (96,962)
Period of extension of transformation of operating structure and steps to achieve cost savings     2 years  
Legacy Portfolio Optimization        
Other operating income and expense        
Reclassification adjustments of foreign currency translation amounts previously classified within other comprehensive income, included in expenses from strategic transactions and programs € (45,083) € 14 € (45,083) € (96,962)